RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema
CompanyDrug

RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema

AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure
CompanyDeals

AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure

C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar
CompanyDeals

C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar

NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs
Policy / Regulatory

NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs

MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint
CompanyDeals

MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint

Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology
CompanyDeals

Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology

AccurEdit Therapeutics Raises $75 M Series A, Secures Strategic Partners for Gene‑Editing Platform
CompanyDeals

AccurEdit Therapeutics Raises $75 M Series A, Secures Strategic Partners for Gene‑Editing Platform

Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection
CompanyDrug

Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection

Ipsen Launches BYLVAY in China for Rare Liver Disease
CompanyDrug

Ipsen Launches BYLVAY in China for Rare Liver Disease

TJ Biopharma Secures Series C2 Funding to Accelerate Autoimmune and Oncology Pipeline
CompanyDeals

TJ Biopharma Secures Series C2 Funding to Accelerate Autoimmune and Oncology Pipeline

Full‑Life Technologies Raises $77 M in Series C and Debt Funding
CompanyDeals

Full‑Life Technologies Raises $77 M in Series C and Debt Funding

GSK Names Luke Miels as CEO to Drive Growth
Company

GSK Names Luke Miels as CEO to Drive Growth